The results mark a significant shift for a patient population that historically faced poor outcomes, with a five-year survival rate of just 8 percent. While chemotherapy alone resulted in a median overall survival of 27.9 months, the addition of the bispecific antibody RYBREVANT extended that period by more than six months. This improvement occurred even as 76 percent of patients in the chemotherapy-only group eventually switched to RYBREVANT following disease progression.

Dr. Chul Kim of MedStar Georgetown University Hospital noted that the durability of the response is a critical factor, as patients are remaining on treatment for years. The dual-targeting approach, which engages both the EGFR and MET pathways, aims to address the specific drivers of tumor growth and resistance that have traditionally made this mutation difficult to treat. The findings, published as part of the PAPILLON trial, establish a new benchmark for first-line therapy in this aggressive form of non-small cell lung cancer.